Astria Therapeutics (NASDAQ:ATXS) Price Target Raised to $28.00 at Oppenheimer

Astria Therapeutics (NASDAQ:ATXS) had its price target increased by Oppenheimer from $26.00 to $28.00 in a research report sent to investors on Thursday,Benzinga reports. Oppenheimer currently has an outperform rating on the biotechnology company’s stock.

Several other research firms have also recently weighed in on ATXS. HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a research note on Friday, September 27th. Evercore ISI upgraded Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. Wedbush restated an “outperform” rating and issued a $22.00 target price on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Finally, TD Cowen started coverage on Astria Therapeutics in a research note on Monday, July 29th. They issued a “buy” rating and a $35.00 target price for the company. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $25.60.

Astria Therapeutics Trading Down 7.3 %

Shares of NASDAQ:ATXS traded down $0.74 during trading on Thursday, hitting $9.35. 162,120 shares of the company’s stock traded hands, compared to its average volume of 613,426. The company has a market cap of $527.53 million, a price-to-earnings ratio of -4.44 and a beta of 0.71. The company has a 50-day moving average price of $11.44 and a 200-day moving average price of $10.60. Astria Therapeutics has a 52 week low of $4.26 and a 52 week high of $16.90.

Astria Therapeutics (NASDAQ:ATXS) last posted its earnings results on Monday, August 12th. The biotechnology company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.05). On average, analysts predict that Astria Therapeutics will post -1.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Astria Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ATXS. Vanguard Group Inc. raised its position in Astria Therapeutics by 23.4% in the first quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock worth $35,693,000 after acquiring an additional 480,184 shares during the period. Ameritas Investment Partners Inc. grew its stake in Astria Therapeutics by 135.6% during the first quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock valued at $70,000 after acquiring an additional 2,861 shares in the last quarter. American International Group Inc. grew its stake in Astria Therapeutics by 49.4% during the first quarter. American International Group Inc. now owns 24,565 shares of the biotechnology company’s stock valued at $346,000 after acquiring an additional 8,122 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new position in Astria Therapeutics during the first quarter valued at $200,000. Finally, Tidal Investments LLC purchased a new position in shares of Astria Therapeutics in the 1st quarter worth $1,664,000. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.